Android app Apple app link

Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders

By MarketWatch   |   1 month ago
Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders

Opko Health and Entera Bio collaborate on a tablet to target obesity and metabolic disorders. They plan to submit an investigational new drug application for a dual agonist GLP-1/glucagon peptide.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

To become a member, please download and purchase membership through our app.